Target intelligence / Profile preview

25 kDa ookinete surface antigen (Pfs25) (Pfs25)

Target
Pfs25
Molecular classification
Other
01

Overview

The 25 kDa ookinete surface antigen (Pfs25) is a sexual-stage surface protein of the malaria parasite Plasmodium falciparum. It is expressed predominantly on the surface of zygotes and ookinetes within the midgut of the female Anopheles mosquito vector after fertilization. Structurally, Pfs25 is a glycosylphosphatidylinositol (GPI)-anchored protein containing four tandem epidermal growth factor (EGF)-like domains rich in disulfide bonds. Because Pfs25 is not expressed during the asexual blood stages in the human host, it is not exposed to natural immune selection pressure, making it highly conserved among diverse parasite isolates. This conservation makes Pfs25 a leading candidate for the development of malaria transmission-blocking vaccines (TBVs).

Vaccines targeting Pfs25, such as Pfs25-EPA and Pfs25-IMX313, aim to elicit high titers of functional antibodies in the human host. When a mosquito feeds on a vaccinated individual, it ingests these antibodies along with gametocytes. Within the mosquito midgut, the antibodies bind to Pfs25 on the surface of the developing zygotes and ookinetes, preventing their traversal of the midgut epithelium and subsequent development into oocysts, thereby breaking the cycle of malaria transmission. Passive administration of transmission-blocking monoclonal antibodies (such as 4B7) is also being explored. Major challenges in targeting Pfs25 include its poor immunogenicity as a monomeric protein, which necessitates conjugation to carrier proteins (like ExoProtein A) or presentation on virus-like particles, and the rapid decay of antibody titers, which requires potent adjuvants that can sometimes cause systemic reactogenicity.

Other names
25 kDa sexual-stage surface antigen of Plasmodium falciparum25 kDa ookinete surface antigenSurface protein Pfs25Plasmodium falciparum surface protein Pfs25Pfs25P25
02

Mechanism of action

Elicitation of transmission-blocking antibodies that bind to the parasite surface in the mosquito midgut, preventing ookinete development and oocyst maturation

03

Biological functions

OtherImmune response
04

Disease associations

Infection
05

Safety considerations

Systemic reactogenicity (e.g., erythema nodosum when formulated with certain adjuvants like Montanide ISA 51)Poor immunogenicity of monomeric recombinant protein requiring complex conjugation or nanoparticle deliveryRapid decline of antibody titers post-vaccination requiring frequent boostingHypersensitivity reactions
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Anti-Pfs25 IgG antibody titerTransmission-blocking activity (TBA)Transmission-reducing activity (TRA)Oocyst count reduction in Standard Membrane Feeding Assay (SMFA)

Beyond the preview

Go deeper on 25 kDa ookinete surface antigen (Pfs25) (Pfs25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 25 kDa ookinete surface antigen (Pfs25) (Pfs25).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call